Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Nieto Y, et al. Among authors: champlin r. Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2. Biol Blood Marrow Transplant. 2018. PMID: 29501779 Free PMC article. Clinical Trial.
Early myeloablative therapy for multiple myeloma.
Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Alexanian R, et al. Among authors: champlin r. Blood. 1994 Dec 15;84(12):4278-82. Blood. 1994. PMID: 7994043 Free article.
Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine.
Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton D. Deisseroth AB, et al. Among authors: champlin r. Hum Gene Ther. 1993 Feb;4(1):71-85. doi: 10.1089/hum.1993.4.1-71. Hum Gene Ther. 1993. PMID: 8461383 Clinical Trial. No abstract available.
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. van Besien KW, et al. Among authors: champlin r. Am J Med. 1996 Mar;100(3):299-307. doi: 10.1016/S0002-9343(97)89488-0. Am J Med. 1996. PMID: 8629675
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, Norfleet F, Chan KW, Champlin R, Körbling M. Anderlini P, et al. Among authors: champlin r. Transfusion. 1996 Jul;36(7):590-5. doi: 10.1046/j.1537-2995.1996.36796323057.x. Transfusion. 1996. PMID: 8701453
1,166 results